Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for testing in the clinical and non-clinical markets. Its systems enable molecular testing for organisms and genetic-based diseases by automating manual laboratory procedures. The company primarily offers GeneXpert system that integrates sample preparation in addition to DNA amplification and detection. The GeneXpert system is designed for reference laboratories, hospital central laboratories, and satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. The company offers GeneXpert system for testing in the areas of healthcare-associated infections, critical infectious disease, sexual health, virology, oncology, and genetics. It also provides SmartCycler system, which integrates DNA amplification and detection to allow analysis of a sample; and Xpert tests for use on the GeneXpert system. The company sells its products through its direct sales force and distributors worldwide. It has collaboration arrangements with Life Technologies Corporation to develop reagents for use in the USPS BDS program; Foundation for Innovative New Diagnostics to develop tests that can detect mycobacterium tuberculosis and associated rifampin resistance from human sputum samples; and Paul G. Allen Family Foundation and the Bill & Melinda Gates Foundation to develop Xpert Ebola, an Ebola test to be run on its GeneXpert Systems. The company was incorporated in 1996 and is headquartered in Sunnyvale, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• No BuyIns.Net Alerts Available for CPHD